Biolife solutions stock.

First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...

Biolife solutions stock. Things To Know About Biolife solutions stock.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.Dec 1, 2023 · View BioLife Solutions, Inc BLFS investment & stock information. Get the latest BioLife Solutions, Inc BLFS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.BLFE | Complete BioLife Sciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Dec 1, 2023 · BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists).

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.For BioLife Solutions stock forecast for 2031, 12 predictions are offered for each month of 2031 with average BioLife Solutions stock forecast of $65.5, a high forecast of $126.33, and a low forecast of $32.2. The average BioLife Solutions stock forecast 2031 represents a 412.95% increase from the last price of $12.7700004577637.

Under the terms of the agreement, BioLife will pay $15 million in cash and $15 million in newly issued shares of BioLife common stock for 100% of the outstanding shares of SciSafe. ... About BioLife Solutions BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.Stock analysis for BioLife Solutions Inc (BLFS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The BioLife Solutions stock price gained 3.76% on the last trading day (Friday, 24th Nov 2023), rising from $13.57 to $14.08. During the last trading day the stock fluctuated 11.10% from a day low at $12.79 to a day high of $14.21. The price has risen in 6 of the last 10 days and is up by 23.62% over the past 2 weeks.

The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.

BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTCBioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.... Stock, $0.001 par value of BioLife Solutions, Inc. shall be filed on behalf of the undersigned. November 27, 2020. (Date). Casdin Capital, LLC. By: /s/ Eli ...Get the latest BioLife Solutions Inc (BLFS) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and earnings per share for the fiscal Q2 2023 ended 6/30/23. BioLife Solutions, Inc. Common Stock (BLFS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BOTHELL, Wash., July 7, 2020 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price ...BAC Vs BLFS: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. Start now and save 50% for the first 3 months save 50% for the first 3 months. Ticker. Company. Your search produced no matches. We currently support US stocks and STOXX Europe 600 …BioLife Solutions's headquarters are located at 3303 Monte Villa Pkwy Ste 310, Bothell, Washington, 98021, United States What is BioLife Solutions's phone number? BioLife Solutions's phone number is (425) 402-1400 What is BioLife Solutions's stock symbol?BioLife Solutions Inc (ISIN: US09062W2044, WKN: A1XCF2): ✓ Precio Acciones BioLife Solutions Inc ✓ Rendimiento de Dividendos y Fechas, ✓ News ✓ Plan de ...

of class-defining solutions. Solutions. Our platforms enable significant improvement in shelf life and post-preservation viability and function of biologic materials. Cell Processing. ... BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA; T +1.866.424.6543 or 425.402.1400; F +1.425.402.1433 ...According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.

BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BLFS is experiencing ...22 mar 2021 ... BioLife expects the acquisition of Stirling to impact the Company's financial performance as follows: 2021 revenue contribution is expected to ...BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.Stock Symbol NASDAQ:BLFS ; ... Phone Number 425-402-1400; BioLife Solutions is located in Bothell, Washington, on a high-tech campus that has its roots as a dairy farm. They design, manufacture, and market proprietary and generic cGMP biopreservation media products for cells, tissues, and organs. They also perform contract research and offer ...On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...Press Releases. BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022. Decision to Explore Strategic Alternatives for Ultra-Low ...The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.

BLFS BioLife Solutions stock chart. #fintwits #money #wallstreet #stockmarket #stocks. 0 points. 1 comment. 1. 0 comments. share. save. 2. Posted by 2 years ago. I want to buy a trading bot, any recommendations here? 2. 3 comments. share. save. 1. Posted by 2 years ago. Adam Khoo FX trading. Hello! I got some courses a while back and have ...

While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...

Jan 6, 2023 · While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ... Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third ...Buy BioLife Solutions Stock. BioLife Solutions is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $13.54 – an increase of 2.11% over the previous day.According to the issued ratings of 5 analysts in the last year, the consensus rating for BioLife Solutions stock is Buy based on the current 5 buy ratings for BLFS. The average twelve-month price prediction for BioLife Solutions is $24.60 with a high price target of $28.00 and a low price target of $22.00. Learn more on BLFS's analyst rating ...A high-level overview of BioLife Solutions, Inc. (BLFS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …Mar 22, 2021 · BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ... Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Mar 22, 2021 · BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ... BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.Instagram:https://instagram. books on day tradingsingapore alinesbest tax software for self employedlument finance trust 5 Wall Street analysts have issued 1 year target prices for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $28.00. On average, they expect the company's stock price to reach $24.60 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View analysts price targets for BLFS or ... analyze stockhow much titanium is in the iphone 15 When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock. best dentist for crowns 5 Wall Street analysts have issued 1 year target prices for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $28.00. On average, they expect the company's stock price to reach $24.60 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View analysts price targets for BLFS or ... BioLife Solutions GAAP EPS of -$0.17 beats by $0.09, revenue of $36.22M misses by $1.98M SA News Mon, May 09, 2022 BioLife Solutions gains as Oppenheimer upgrades on valuation